Showing 2 of 10 years of data. Sign up free for 3 years, or upgrade for full access.
View Plans2-year trend showing gross, operating, and net profit margins
Ajanta Pharma Limited's net profit margin of 19.4% in FY2025 reflects good profitability, with operating margin at 25.5% and gross margin at 77.4%.
In FY 2025, Ajanta Pharma Limited posted a gross margin of 77.4%, an operating margin of 25.5%, a net margin of 19.4%. Gross Margin = (Revenue - COGS) / Revenue; Operating Margin = EBIT / Revenue; Net Margin = Net Income / Revenue. Typical healthy ranges: Gross 20-40%, Operating 10-20%, Net 5-10%+. Consistent or improving margins indicate strong competitive positioning.
2-year trend showing revenue, gross profit, and net profit
Ajanta Pharma Limited's revenue grew 10.5% to 47.43B and net profit grew 12.8% to 9.20B YoY in FY2025, indicating healthy business momentum.
In FY 2025, Ajanta Pharma Limited's revenue grew by 10.5% year-over-year. Revenue is total income from operations. Gross Profit is revenue minus cost of goods. Net Profit is the bottom line after all expenses. Consistent growth across all three signals a healthy, expanding business.
2-year trend showing shareholder returns
Ajanta Pharma Limited's ROE of 24.3% in FY2025 indicates excellent capital efficiency.
In FY 2025, Ajanta Pharma Limited reported an ROE of 24.3%. ROE = (Net Income / Shareholders' Equity) x 100. Measures how efficiently the company turns equity into profit. Above 15% is generally strong; above 25% is excellent. Very high ROE may signal high leverage — check alongside debt levels.
2-year trend comparing profitability with cash generation
Ajanta Pharma Limited's FCF/NI ratio of 0.91x in FY2025 indicates reasonable cash generation relative to profits.
In FY 2025, Ajanta Pharma Limited's free cash flow trailed net income. Free Cash Flow = Operating Cash Flow - Capital Expenditure. When FCF exceeds net income, it suggests high-quality, cash-backed earnings. Persistent gaps may indicate aggressive accounting or heavy capex needs.
2-year trend comparing profitability with cash from operations
Ajanta Pharma Limited's OCF/NI ratio of 1.26x in FY2025 indicates sound cash management with earnings well-backed by cash.
In FY 2025, Ajanta Pharma Limited's operating cash flow exceeded net income. Operating Cash Flow is the actual cash from core operations. OCF exceeding net income signals strong cash collection. OCF trailing net income may indicate aggressive revenue recognition or working capital issues.
Measure a company's financial leverage, liquidity, and ability to meet financial obligations.
2-year trend showing short-term liquidity position
Ajanta Pharma Limited's current ratio of 2.85x in FY2025 indicates healthy short-term liquidity.
In FY 2025, Ajanta Pharma Limited reported a current ratio of 2.85. Current Ratio = Current Assets / Current Liabilities. Measures short-term liquidity. A ratio of 1.5-3.0 is generally healthy; below 1.0 signals liquidity risk; above 3.0 may indicate underutilized assets.
2-year trend showing ability to service debt
Ajanta Pharma Limited's interest coverage ratio of 58.4x in FY2025 indicates comfortable debt servicing capacity.
In FY 2025, Ajanta Pharma Limited reported an interest coverage ratio of 58.4x. Interest Coverage = EBIT / Interest Expense. Shows how many times operating profit covers interest payments. Above 5x is comfortable; below 1.5x signals potential difficulty servicing debt.
2-year trend showing financial leverage and capital structure
Ajanta Pharma Limited's debt-to-equity ratio of 0.01x in FY2025 reflects a conservative, low-leverage capital structure.
In FY 2025, Ajanta Pharma Limited reported a debt-to-equity ratio of 0.01. Debt-to-Equity = Total Debt / Total Equity. Below 1.0 is conservative; 1.0-2.0 is moderate; above 2.0 indicates higher financial risk. Capital-intensive industries naturally carry higher ratios.
2-year trend showing total debt with year-over-year changes
Ajanta Pharma Limited's debt increased 34.4% YoY in FY2025 — rising leverage demands close monitoring.
In FY 2025, Ajanta Pharma Limited's total debt increased by 34.4% year-over-year. Total Debt includes short-term debt, long-term loans, debentures, and capital leases. YoY changes (shown as percentages) reveal whether the company is leveraging up or deleveraging.
Year-over-year change in diluted shares outstanding
Ajanta Pharma Limited's diluted shares decreased 0.7% YoY in FY2025, indicating shareholder-friendly buybacks.
Over 2 years (FY2024–FY2025), diluted shares decreased 0.7% from 126.01M to 125.17M, reflecting long-term shareholder value creation.
In FY 2025, Ajanta Pharma Limited's diluted shares decreased by 0.7% year-over-year. Diluted Shares accounts for stock options, warrants, and convertibles. Positive YoY change means dilution (red); negative means buybacks (green). Consistent dilution above 5% annually is a red flag.
You're viewing 2 years of data. Upgrade to access 10 years of financial ratios, margins, and performance metrics.
Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: FY 2025